Cargando…

Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma

OBJECTIVE: Somatic TP53 mutation (TP53(mut)) is a characteristic finding in high-grade serous ovarian cancer (HGSOC). The aim of this study was to assess the clinical efficacy and utility of TP53(mut) circulating tumor DNA (ctDNA) monitoring as a biomarker for managing HGSOC. METHODS: TP53(muts) wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yong-Man, Lee, Shin-Wha, Lee, Young-Jae, Lee, Ha-Young, Lee, Jong-Eun, Choi, Eun-Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424844/ https://www.ncbi.nlm.nih.gov/pubmed/30887755 http://dx.doi.org/10.3802/jgo.2019.30.e32

Ejemplares similares

Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer
por: Park, Yu Ran, et al.
Publicado: (2018)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer
por: Lee, Shin-Wha, et al.
Publicado: (2021)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer
por: Park, Eunhyang, et al.
Publicado: (2022)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
por: Chien, Jeremy, et al.
Publicado: (2015)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
por: Parkinson, Christine A., et al.
Publicado: (2016)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
por: Wojnarowicz, Paulina M., et al.
Publicado: (2012)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Diagnostic and prognostic role of circulating neutrophil extracellular trap markers and prekallikrein in patients with high-grade serous ovarian cancer
por: Kim, Jisoo G., et al.
Publicado: (2022)

Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue
por: Nam, Eun Ji, et al.
Publicado: (2016)

The expression and function of toll-like receptors (TLRs) in ovarian cancer cell lines
por: Lee, Shin-Wha, et al.
Publicado: (2015)

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
por: Chung, Young Shin, et al.
Publicado: (2018)

Dysregulation of X Chromosome Inactivation in High Grade Ovarian Serous Adenocarcinoma
por: Kang, Jun, et al.
Publicado: (2015)

Peritoneal Carcinosarcoma and Ovarian Papillary Serous Carcinoma Are the Same Origin: Analysis of TP53 Mutation and Microsatellite Suggests a Monoclonal Origin
por: Woo, Chang Gok, et al.
Publicado: (2014)

Polymorphisms in Apoptosis-Related Genes and TP53 Mutations in Non-Small Cell Lung Cancer
por: Bae, Eun Young, et al.
Publicado: (2011)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

Comprehensive genomic profiling of high‐grade serous ovarian carcinoma from Chinese patients identifies co‐occurring mutations in the Ras/Raf pathway with TP53
por: Zhong, Fangfang, et al.
Publicado: (2019)

Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis
por: Paracchini, Lara, et al.
Publicado: (2020)

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
por: Bischof, Katharina, et al.
Publicado: (2019)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

The G199X and V157fs mutations in the TP53 gene promote malignancy in serous ovarian cancer: an analysis using whole-exome sequencing
por: Su, Dan, et al.
Publicado: (2021)

High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer
por: Kim, Jeong Eun, et al.
Publicado: (2021)

Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nv84qr5pcgs2l6k284p9a1ur2g